pyrazines has been researched along with Lipodystrophy in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Konishi, H; Kyohara, M; Okuyama, T; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y; Yamazaki, S | 1 |
Cicalini, S; D'Abbraccio, M; d'Ettorre, G; Di Biagio, A; Maggi, P; Martinelli, C; Nunnari, G; Rusconi, S; Sighinolfi, L; Spagnuolo, V; Squillace, N | 1 |
Ditlevsen, S; Lindegaard, B; Mittendorfer, B; Pedersen, BK; Plomgaard, P | 1 |
Aliabadi, N; Breu, J; Grinspoon, S; Hadigan, C; Meininger, G; Rabe, J | 1 |
1 review(s) available for pyrazines and Lipodystrophy
Article | Year |
---|---|
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Topics: Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Growth Hormone-Releasing Hormone; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipodystrophy; Pyrazines; Risk Factors | 2017 |
2 trial(s) available for pyrazines and Lipodystrophy
Article | Year |
---|---|
Acute reduction of lipolysis reduces adiponectin and IL-18: evidence from an intervention study with acipimox and insulin.
Topics: Adiponectin; Cross-Over Studies; Female; Humans; Insulin; Interleukin-18; Lipodystrophy; Lipolysis; Male; Middle Aged; Pyrazines | 2013 |
Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Topics: Adipose Tissue; Adult; Area Under Curve; Fasting; Fatty Acids; Glucose Tolerance Test; HIV Infections; Humans; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Lipodystrophy; Lipolysis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Viscera | 2003 |
1 other study(ies) available for pyrazines and Lipodystrophy
Article | Year |
---|---|
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.
Topics: Animals; Cell Proliferation; Dietary Supplements; Energy Metabolism; Fatty Liver; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Imidazoles; Insulin-Secreting Cells; Leptin; Lipodystrophy; Mice; Pyrazines; Safety-Based Drug Withdrawals; Time Factors; Tomography, X-Ray Computed | 2017 |